Study title: Open, multicentre study to evaluate the efficacy and tolerability of leuprorelin acetate 3,75 mg (enantone depot) in central precocious puberty treatment
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Endocrine System Diseases [C19] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: LEUPRORELIN | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: TAP-144-SR (1M)/ENA 027 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |